Characterization of variants of uncertain significance is the main limitation of genetic diagnostics by NGS. Mitochondrial Diseases (MDs) are the most heterogeneous group of metabolic diseases with hundreds of involved reactions making conformational tests challenging. Omics-Analysis usually give partial evidence about the effects of the identified variants, but often confirmation is required by targeted assays in either patient samples or model systems.